EVP R&D, Chief Medical Officer
Mon, Jun 1, 2026
Jun 1
9,000 shares @ $41.67
Decreased holdings by -10.40%
23rd largest trade (out of 157)
Planned (10b5-1)
“This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.”Form 4 footnote
Trade made by an officer
Executed under a pre-scheduled Rule 10b5-1 plan
Price 35% above 200-day moving average